On November 14, Cidara Therapeutics announced its sale to Merck for approximately $9.2B. We are honored to have served as financial advisor to Cidara Therapeutics.
Goldman Sachs Investment Banking Goldman Sachs, a great deal! Well done! 😃 👍 🤝 👏
Thank you to Goldman Sachs for your robust representation and authentic confidence in the ability of CD388 to transform the prevention of seasonal flu!
Congratulations 🍾🎈🎉🎊
Steep premium, no CVR - nicely negotiated!
Congratulations to Cidara Therapeutics on their successful sale to Merck! It's a significant achievement, and your role as their financial advisor played a vital part in this milestone. Exciting times ahead!
Congratulations!!!
Wow, that’s massive. A $9.2B deal doesn’t happen every day. Huge shoutout to the Cidara team and to your team for advising on such a big win. Really shows how strong execution + innovation pays off.
Biopharma Entrepreneur
1wMany thanks to the Goldman and Evercore teams for their solid guidance throughout the process to get us to this terrific outcome. Importantly, the landscape for flu prevention has taken a giant step forward!